Testing a combination treatment for advanced kidney cancer and melanoma

Plain-English translation of NCT07634380 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated August 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing whether , an oral medication taken daily, can work better when combined with (an immunotherapy given through an IV infusion every three weeks) to treat advanced kidney cancer or melanoma. The study focuses on people whose cancer has stopped responding to previous PD-1 or PD-L1 immunotherapy treatments. Researchers will first test different doses of the medication to find the safest amount, then expand the study to see how well this combination works against the cancer.

Many people with advanced kidney cancer and melanoma develop resistance to standard immunotherapy treatments. This trial explores whether adding this medication might help the body's immune system fight back against cancers that have become resistant to current therapies.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced (metastatic) kidney cancer with a clear cell component or advanced melanoma that has progressed despite treatment with PD-1 or PD-L1 immunotherapy
you received at least 2 doses of a standard anti-PD-1 or anti-PD-L1 immunotherapy before your cancer worsened
your cancer has shown progression either within 12 weeks of your last immunotherapy dose (refractory disease) or more than 12 weeks after your last dose (relapsed disease)
you have measurable disease visible on imaging scans (at least one lesion 10mm or larger)
you are 18 years or older and able to understand and follow the study requirements
you have recovered adequately from any prior major surgery before starting the study

You likely don't qualify if…

you have an active autoimmune disease that required systemic treatment (with steroids, immunosuppressive drugs, or disease-modifying medications) in the past 2 years
you are pregnant, breastfeeding, or not using effective birth control (if you can become pregnant)
you have not recovered to acceptable levels from side effects or complications from prior surgery
you have uveal melanoma (melanoma in the eye) or mucosal melanoma (melanoma of mucous membranes)
your kidney cancer includes a neuroendocrine component

What participation looks like

You would take as a daily oral pill and receive infusions through an IV every three weeks. The study has two phases: first, researchers will test increasing doses of the daily medication with a small group to find the safest dose, and then a larger group will receive that safe dose to evaluate how well the combination works. Throughout the trial, you'll have regular clinic visits for blood tests, imaging scans, and health monitoring to track how you're responding and watch for any side effects.

AI-generated summary from trial data · Aug 5, 2026 · Not medical advice

Trial locations(1 site)

United States

University of Iowa, Iowa City, Iowa